The dual antiplatelet therapy trial after the FDA update: Noncardiovascular deaths, cancer and optimal treatment duration

Cardiology (Switzerland)

Volumn 132, Issue 2, 2015, Pages 74-80

  Serebruany, Victor L ^a   Cherepanov, Vasily ^a   Golukhova, Elena Z ^b   Kim, Moo Hyun ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^c Dong A University College of Medicine   (South Korea)

Author keywords

Cancer; Clinical trials; Clopidogrel; Noncardiovascular deaths; Prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO; PRASUGREL; THIENOPYRIDINE DERIVATIVE; VORAPAXAR;

ARTICLE; CANCER RISK; DEATH; DRUG WITHDRAWAL; DUAL ANTIPLATELET THERAPY; HAZARD RATIO; MALIGNANT NEOPLASM; PRIORITY JOURNAL; STENT THROMBOSIS; TREATMENT DURATION;

EID: 84933557896     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000431356     Document Type: Article

References (6)

1. Mauri L, Kereiakes DJ, Normand SL, Wiviott SD, Cohen DJ, Holmes DR, Bangalore S, Cutlip DE, Pencina M, Massaro JM: Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010; 160: 1035-1041.
2. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators: Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155-2166.
3. FDA Drug Safety Communication: FDA reviews long-term antiplatelet therapy as preliminary trial data shows benefits but a higher risk of non-cardiovascular death. http://www. fda.gov/drugs/drugsafety/ucm423079.htm (accessed January 16, 2015).
4. Food and Drug Administration: Clinical review on cancer risk. http://www.accessdata.fda. gov/drugsatfda-docs/nda/2015/206316Orig1 Orig2s000MedR.pdf (accessed March 3, 2015).
5. Food and Drug Administration: Briefing document, 3 February 2009 Meeting of FDA Cardiovascular and Renal Drugs Advisory Committee on prasugrel. http://www.fda. gov/downloads/advisorycommittees/committeesmeetingmaterials/ drugs/cardiovascularandrenaldrugsadvisorycommittee/ ucm181185.pdf (accessed January 16, 2015).
6. NDA 294-886: Cross-Discipline Team Leader review on vorapaxar, 18 April 2014. http:// www.accessdata.fda.gov/drugsatfda-docs/ nda/2014/204886Orig1s000SumR.pdf (accessed January 17, 2015).